BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38451676)

  • 1. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation: Erratum.
    Anticancer Drugs; 2024 Apr; 35(4):383. PubMed ID: 38451676
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
    Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
    Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Concern: Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
    Cancer Sci; 2024 Jun; 115(6):2086. PubMed ID: 38538295
    [No Abstract]   [Full Text] [Related]  

  • 4. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY; Sun GB; Wang YJ; Yan F
    Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR
    Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; GĂ©rard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
    Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
    Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
    Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
    Chen X; Shi X; Zhao C; Li X; Lan X; Liu S; Huang H; Liu N; Liao S; Zang D; Song W; Liu Q; Carter BZ; Dou QP; Wang X; Liu J
    Oncotarget; 2014 Oct; 5(19):9118-32. PubMed ID: 25193854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
    Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
    Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
    Acharya S; Sahoo SK
    J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
    Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
    Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM; Liu FH; Lee YL; Huang HM
    PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.